Hereditary severe von Willebrand Disease in children research hub

A Phase 3, Prospective, Multicenter, Uncontrolled, Open-Label Clinical Study to Determine the Efficacy, Safety, and Tolerability of rVWF with or without ADVATE in the Treatment and Control of Bleeding Episodes, the Efficacy and Safety of rVWF in Elective and Emergency Surgeries, and the Pharmacokinetics (PK) of rVWF in Children Diagnosed with Severe von Willebrand Disease

This study looks at a new medicine called VEYVONDI for children with severe von Willebrand Disease. It checks if the medicine stops bleeds, how safe it is, and how it works in the body, including during surgery when given with or without another medicine called ADVATE.